Dr. Lal PathLabs Balance Sheet Health
Financial Health criteria checks 5/6
Dr. Lal PathLabs has a total shareholder equity of ₹18.1B and total debt of ₹3.0B, which brings its debt-to-equity ratio to 16.6%. Its total assets and total liabilities are ₹24.5B and ₹6.4B respectively. Dr. Lal PathLabs's EBIT is ₹4.4B making its interest coverage ratio -323.5. It has cash and short-term investments of ₹9.0B.
Key information
16.6%
Debt to equity ratio
₹2.99b
Debt
| Interest coverage ratio | -323.5x |
| Cash | ₹8.97b |
| Equity | ₹18.06b |
| Total liabilities | ₹6.39b |
| Total assets | ₹24.45b |
Recent financial health updates
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
May 25Recent updates
What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You
May 01Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Apr 13These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next
Feb 04Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price
Dec 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around
Oct 12Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 10Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital
Feb 13Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends
Sep 21These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00
Jul 31Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 23Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?
Jun 11These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
May 25Do Dr. Lal PathLabs's (NSE:LALPATHLAB) Earnings Warrant Your Attention?
Apr 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) A Risky Investment?
Feb 17With EPS Growth And More, Dr. Lal PathLabs (NSE:LALPATHLAB) Is Interesting
Jan 20Why You Should Care About Dr. Lal PathLabs' (NSE:LALPATHLAB) Strong Returns On Capital
Dec 06Here's Why I Think Dr. Lal PathLabs (NSE:LALPATHLAB) Might Deserve Your Attention Today
Oct 13Financial Position Analysis
Short Term Liabilities: LALPATHLAB's short term assets (₹10.8B) exceed its short term liabilities (₹4.7B).
Long Term Liabilities: LALPATHLAB's short term assets (₹10.8B) exceed its long term liabilities (₹1.7B).
Debt to Equity History and Analysis
Debt Level: LALPATHLAB has more cash than its total debt.
Reducing Debt: LALPATHLAB's debt to equity ratio has increased from 0% to 16.6% over the past 5 years.
Debt Coverage: LALPATHLAB's debt is well covered by operating cash flow (173.7%).
Interest Coverage: LALPATHLAB earns more interest than it pays, so coverage of interest payments is not a concern.